scholarly journals Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database

Aging ◽  
2020 ◽  
Vol 12 (19) ◽  
pp. 19711-19739
Author(s):  
Floor Swart ◽  
Giampaolo Bianchi ◽  
Jacopo Lenzi ◽  
Marica Iommi ◽  
Lorenzo Maestri ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Real World ◽  
The Elderly ◽  
Administrative Database ◽  
Real World Evidence

Drug interactions in users of tablet vs. oral liquid levothyroxine formulations: a real-world evidence study in primary care

Endocrine ◽  
2017 ◽  
Vol 59 (3) ◽  
pp. 585-592 ◽  
Author(s):  
Valeria Guglielmi ◽  
Alfonso Bellia ◽  
Elisa Bianchini ◽  
Gerardo Medea ◽  
Iacopo Cricelli ◽  
...  
Keyword(s):  
Primary Care ◽  
Drug Interactions ◽  
Real World ◽  
Real World Evidence ◽  
Oral Liquid

scholarly journals MACITENTAN IN THE ELDERLY POPULATION WITH PULMONARY ARTERIAL HYPERTENSION: REAL-WORLD EVIDENCE FROM THE COMBINED OPUS REGISTRY AND ORPHEUS COHORT

CHEST Journal ◽  
2019 ◽  
Vol 156 (4) ◽  
pp. A330-A332 ◽  
Author(s):  
Kelly Chin ◽  
Nick Kim ◽  
Vallerie McLaughlin ◽  
Robert Frantz ◽  
Josanna Rodriguez-Lopez ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Real World ◽  
Elderly Population ◽  
The Elderly ◽  
Real World Evidence ◽  
Pulmonary Arterial

scholarly journals Clopidogrel Drug Interactions and Serious Bleeding: Generating Real‐World Evidence via Automated High‐Throughput Pharmacoepidemiologic Screening

2019 ◽  
Vol 106 (5) ◽  
pp. 1067-1075 ◽  
Author(s):  
Charles E. Leonard ◽  
Meijia Zhou ◽  
Colleen M. Brensinger ◽  
Warren B. Bilker ◽  
Samantha E. Soprano ◽  
...  
Keyword(s):  
Drug Interactions ◽  
High Throughput ◽  
Real World ◽  
Real World Evidence

scholarly journals Reflections on the Use of Perampanel in Epilepsy – Lessons from the Clinic and Real-world Evidence

2017 ◽  
Vol 12 (01) ◽  
pp. 17
Author(s):  
Eugen Trinka ◽  
Mar Carreňo ◽  
◽  
Keyword(s):  
Ampa Receptors ◽  
Real World ◽  
The Elderly ◽  
Cytochrome P450 Enzymes ◽  
Mild Renal Impairment ◽  
Real World Evidence ◽  
Suboptimal Adherence ◽  
Randomised Controlled ◽  
Therapeutic Doses ◽  
Patients With Epilepsy

Optimal epilepsy management includes five important elements: rational treatment selection, efficacy, off-target effects, adherence and interactions and dosing issues. Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl]benzonitrile; E2007) is the first potent, selective, orally-active non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist approved for the treatment of patients with epilepsy. Results from randomised controlled trials and real-world studies of refractory epilepsy populations treated with perampanel showed effective frequency reduction for both focal-onset seizures (without and with secondary generalisation) and for primary generalised tonic-clonic seizures. Perampanel therapeutic doses have been calculated to only inhibit a fraction of AMPA receptors, thereby to enable sufficient seizure control without substantial impairment of neurological function. Further investigation in special subpopulations of people with epilepsy, including the elderly and people with learning disability or psychiatric comorbidities, is warranted. With an average long half-life of 105 hours, perampanel may be more forgiving in circumstances of suboptimal adherence. Perampanel is not a strong inducer or inhibitor of cytochrome P450 enzymes, and dose adjustment is not always required for the elderly or for those with mild renal impairment.

Sign in / Sign up

Export Citation Format

Share Document